Imagine the relentless itch and unsightly hives of chronic spontaneous urticaria (CSU) disrupting your daily life—now picture relief arriving in just three days. That's the game-changing promise of povorcitinib, a breakthrough JAK1 inhibitor, as shared by allergy expert Weilly Soong, MD, at the 2025 American College of Allergy, Asthma, & Immunology (ACAAI) Annual Scientific Meeting in Orlando. For patients battling this unpredictable skin condition, these findings could mean faster, more accessible treatment options that go beyond what's currently available.
During the conference, Dr. Soong, a specialist from AllerVie Health in Birmingham, Alabama, unveiled phase 2 trial results highlighting how povorcitinib swiftly eases the burning itch and raised welts associated with CSU. This oral medication works by selectively inhibiting JAK1, which in turn blocks key inflammatory signals like IL-4, IL-13, IL-31, and IL-6—molecules that fuel the immune overreaction driving these symptoms. Not only did it show quick benefits, but it also maintained a strong safety record, making it an exciting prospect for those tired of trial-and-error treatments.
As part of our live coverage from the event, we caught up with Dr. Soong for an insightful chat. He breaks down the real-world impact of these results, from the speed of symptom relief to why CSU remains such a tough nut to crack for many doctors and patients alike. In this conversation, you'll hear about the timeline for noticeable changes, the urgent gap in effective CSU therapies, and where research on povorcitinib might head next. But here's where it gets controversial: while this drug shows promise, is it ethical to pause its development for business reasons when patients are suffering? We'll touch on that later.
HCPLive: Could you give us a quick overview of the main takeaways from the phase 2 study on povorcitinib in treating chronic spontaneous urticaria?
Dr. Soong: In the group taking the 75 mg dose, we observed a remarkable 22% reduction from baseline in the weekly urticaria activity score (UAS7)—a key measure that tracks overall hive severity and itch intensity over seven days. This improvement was not just noticeable but statistically significant, proving it's not a fluke. Even more impressively, patients reported a sharp drop in itchiness as early as the first two to three days, which is a big deal for anyone who's ever dealt with that constant discomfort.
HCPLive: How soon did folks in the trial start seeing real, meaningful relief from their hives and itching, and how does that stack up against the treatments we have now?
Dr. Soong: By day three, the overall urticaria scores had plummeted to very low levels across the board, offering quick respite from those frustrating symptoms. When you compare this to injectable biologics like omalizumab or dupilumab—which are powerhouses but can take weeks to kick in—povorcitinib acts much more rapidly. It's on par with BTK inhibitors, such as remibrutinib, in terms of speed. That said, without direct comparison trials, we have to be cautious about declaring one superior; it's like comparing apples to oranges until we get more data. And this is the part most people miss: for beginners new to CSU, understanding that faster relief can mean better quality of life, like sleeping through the night or enjoying a meal without worry.
HCPLive: What makes the push for fresh, effective CSU treatments so urgent right now, especially for those who don't respond to antihistamines or even advanced biologics?
Dr. Soong: The landscape for CSU is riddled with gaps—far too many patients are left without solid options, creating a massive unmet need. Think about it: not everyone is eager to jump straight to biologics, especially if their symptoms are recent. Many folks assume CSU flares up from outside factors, like certain foods (say, shellfish or nuts), household cleaners, or even stress from daily activities. They spend months tweaking their environment, all while enduring misery from the hives. This reluctance or delay in starting stronger therapies underscores why we desperately need simpler, oral alternatives that patients might embrace more readily. For those refractory cases—where antihistamines fail and biologics fall short—it's a real crisis, affecting mental health and daily functioning.
HCPLive: As an oral drug targeting the JAK1 pathway selectively, how does povorcitinib fit into the underlying biology of CSU, and in what ways might it stand apart from injectable biologics?
Dr. Soong: At its core, CSU stems from overactive mast cells in the skin—these are like tiny sentinels that mistakenly release histamine and other chemicals, leading to hives and itch without warning. Autoantibodies or self-reactive substances can trigger this chaos. Povorcitinib steps in by inhibiting JAK1, which disrupts the signaling that ramps up mast cell activity and production. It also dials down specific itch pathways linked to chronic urticaria, like those involving IL-31, which is notorious for that persistent prickling sensation. Unlike biologics, which target broader immune players via injections, this oral approach offers convenience—no needles, just a pill—potentially making it easier for long-term use. For newcomers to immunology, picture mast cells as faulty alarms; povorcitinib helps reset them without the hassle of weekly shots.
HCPLive: Were there any other standout results on how well it worked?
Dr. Soong: Absolutely—by the 12-week mark, about 50% of patients achieved a complete hive-free score (zero hives), and 53% reported no itch at all. These numbers highlight not just speed but sustained control, which is crucial for rebuilding confidence in managing the condition day-to-day.
HCPLive: What insights did the trial provide on povorcitinib's safety and how well patients tolerated it?
Dr. Soong: We evaluated three doses: 15 mg, 45 mg, and 75 mg, and all were generally well-received with no major red flags popping up. The side effects that did occur were mild and common, like breakouts of acne, mild headaches, or a simple cold (nasopharyngitis). Interestingly, the three serious adverse events reported were all in the placebo group, suggesting the drug itself didn't contribute. A couple of folks on 45 mg stopped due to tinnitus (a ringing in the ears) or a skin abscess under the surface, and two on 75 mg bowed out because of elevated ferritin levels in their blood (which can signal iron issues) or worsening acne. Overall, it's reassuring for clinicians prescribing it, as these issues were rare and manageable.
HCPLive: Looking ahead, what's on the horizon for povorcitinib's development?
Dr. Soong: This trial underscores that JAK inhibitors like povorcitinib could be a viable new pillar in CSU treatment, offering oral relief where it's sorely needed. However, the CSU program is currently paused as the company shifts focus to other priorities— a decision that might frustrate patients waiting for approvals. Boldly put, is prioritizing profits over patient access the real controversy here? Future steps could involve reigniting trials or comparisons to see if it edges out competitors.
These revelations from ACAAI 2025 spark big questions: Do you think oral JAK inhibitors will revolutionize CSU care, or are biologics still the gold standard? And with programs like this on hold, how should pharma balance innovation with urgency? Share your thoughts in the comments—we'd love to hear if you've experienced CSU or seen these treatments in action.
References
Soong W. Povorcitinib Shows Swift Relief from Hives and Itch in Chronic Spontaneous Urticaria (CSU) Patients. Presented at the 2025 ACAAI Annual Scientific Meeting in Orlando, Florida.
Newsletter
Stay ahead of the curve with thousands of fellow clinicians—sign up for HCPLive's newsletter to get the latest on emerging therapies, cutting-edge trial results, and expert perspectives delivered straight to your inbox.
